* This is the Professional Version. *
Myelodysplastic syndrome (MDS) is group of disorders typified by peripheral cytopenia, dysplastic hematopoietic progenitors, a hypercellular bone marrow, and a high risk of conversion to acute myelogenous leukemia (AML). Symptoms are referable to the specific cell line most affected and may include fatigue, weakness, pallor (secondary to anemia), increased infections and fever (secondary to neutropenia), and increased bleeding and bruising (secondary to thrombocytopenia). Diagnosis is by blood count, peripheral smear, and bone marrow aspiration. Treatment with azacytidine may help; if AML supervenes, it is treated per the usual protocols.
MDS is a group of disorders sometimes referred to as preleukemia, resulting from a somatic mutation of hematopoietic precursors. MDS is similar to but not synonymous with Philadelphia chromosome–negative chronic myelogenous leukemia, chronic myelomonocytic leukemia, and agnogenic myeloid metaplasia. Etiology is often unknown, but risk is increased with exposure to benzene, radiation, and chemotherapeutic agents (particularly long or intense regimens and those involving alkylating agents and epipodophyllotoxins).
MDS is characterized by clonal proliferation of hematopoietic cells, including erythroid, myeloid, and megakaryocytic forms. The bone marrow is normal or hypercellular, and ineffective hematopoiesis can cause anemia (most common), neutropenia, thrombocytopenia, or a combination. The disordered cell production is also associated with morphologic cellular abnormalities in bone marrow and blood. Extramedullary hematopoiesis may occur, leading to hepatomegaly and splenomegaly. Myelofibrosis is occasionally present at diagnosis or may develop during the course of MDS. Classification is by blood and bone marrow findings (see Table: Myelodysplastic Syndrome Bone Marrow Findings and Survival). The MDS clone is unstable and tends to progress to AML.
Myelodysplastic Syndrome Bone Marrow Findings and Survival
Symptoms tend to reflect the most affected cell line and may include pallor, weakness, and fatigue (anemia); fever and infections (neutropenia); and increased bruising, petechiae, epistaxis, and mucosal bleeding (thrombocytopenia). Splenomegaly and hepatomegaly are common. Symptoms may also be referable to other underlying disorders; eg, in elderly patients with preexisting cardiovascular disorders, anemia from MDS may exacerbate anginal pain.
MDS is suspected in patients (especially the elderly) with refractory anemia, leukopenia, or thrombocytopenia. Cytopenias secondary to congenital disorders, vitamin deficiencies, or drug adverse effects must be ruled out. Diagnosis is by examining peripheral blood and bone marrow and identifying morphologic abnormalities in 10 to 20% of cells of a particular lineage.
Anemia is the most common feature, associated usually with macrocytosis and anisocytosis. With automatic cell counters, these changes are indicated by an increased MCV and RBC distribution width. Some degree of thrombocytopenia is usual; on peripheral smear, platelets vary in size, and some appear hypogranular. The WBC count may be normal, increased, or decreased. Neutrophil cytoplasmic granularity is abnormal, with anisocytosis and variable numbers of granules. Eosinophils also may have abnormal granularity. Pseudo Pelger-Huët cells (hyposegmented neutrophils) may be seen. Monocytosis is characteristic of the chronic myelomonocytic leukemia subgroup, and immature myeloid cells may occur in the less well differentiated subgroups. The cytogenetic pattern is usually abnormal, with one or more clonal cytogenetic abnormalities often involving chromosomes 5 or 7.
Azacitidine relieves symptoms, decreases the rate of transformation to leukemia and the need for transfusions, and probably improves survival. Other therapy is supportive, including RBC transfusions as indicated, platelet transfusions for bleeding, and antibiotic therapy for bacterial infection. Deoxyazacitidine, a hypomethylating agent, is sometimes effective, even in patients who do not respond to azacitidine. In some patients, erythropoietin to support RBC needs, granulocyte colony-stimulating factor to manage severe symptomatic granulocytopenia, and, when available, thrombopoietin for severe thrombocytopenia can serve as important hematopoietic support but have not increased survival.
Allogeneic stem cell transplantation is the treatment of choice for young patients, and nonablative allogeneic bone marrow transplantations are now being studied for patients > 50 yr. Response of MDS to chemotherapy, typically regimens similar to those used for AML, is similar to that of AML after age and karyotype are considered.
Myelodysplastic syndrome is a disorder of hematopoietic cell production involving clonal proliferation of an abnormal precursor cell.
Patients usually present with a deficiency of red cells (most common), white cells, and/or platelets.
Transformation to acute myelogenous leukemia is common.
Azacitidine may ameliorate symptoms and decrease the rate of transformation to acute leukemia.
Stem cell transplantation is the treatment of choice in young patients.
Drug NameSelect Trade
* This is the Professional Version. *